Durvalumab
D419MC00004
Phase 3 small_molecule active
Quick answer
Durvalumab for Non Small Cell Lung Cancer NSCLC is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Non Small Cell Lung Cancer NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active